IOVA stock news
This page provides real-time market news, earnings updates, and company announcements related to Iovance Biotherapeutics, Inc. (IOVA).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-03 09:49 EST
Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data
Finviz2026-02-18 01:42:58
Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?
Finviz2026-02-19 15:00:06
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Finviz2026-02-20 22:18:15
Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive
Finviz2026-02-23 15:00:11
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
Finviz2026-02-24 12:03:59
Iovance Biotherapeutics recently announced that its tumor-infiltrating lymphocyte (TIL) therapy for soft tissue sarcoma has achieved positive results in its first clinical trial.
老虎证券2026-02-24 12:23:02
Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.
老虎证券2026-02-24 12:23:04
Data released by Iovance Biotherapeutics, Inc. shows that its core therapy Lifileucel demonstrates a favorable safety profile.
老虎证券2026-02-24 12:24:34
Iovance Biotherapeutics: Fourth Quarter Financial Overview
101 finance2026-02-24 12:33:41
Iovance Biotherapeutics Explodes Over 20% - Early Trial Data Sparks Investor Frenzy
Finviz2026-02-24 19:18:41
Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year?
101 finance2026-02-26 15:46:09
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success
Finviz2026-02-26 19:30:40
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
Finviz2026-02-24 12:03:59
Iovance Biotherapeutics recently announced that its tumor-infiltrating lymphocyte (TIL) therapy for soft tissue sarcoma has achieved positive results in its first clinical trial.
老虎证券2026-02-24 12:23:02
Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.
老虎证券2026-02-24 12:23:04
Data released by Iovance Biotherapeutics, Inc. shows that its core therapy Lifileucel demonstrates a favorable safety profile.
老虎证券2026-02-24 12:24:34
Iovance Biotherapeutics: Fourth Quarter Financial Overview
101 finance2026-02-24 12:33:41
Iovance Biotherapeutics Explodes Over 20% - Early Trial Data Sparks Investor Frenzy
Finviz2026-02-24 19:18:41
Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year?
101 finance2026-02-26 15:46:09
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success
Finviz2026-02-26 19:30:40
IOVA stock chart
IOVA stock detailsIOVA stock price change
On the last trading day, IOVA stock closed at 3.86 USD, with a price change of 1.85% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more